Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Deregulated protein tyrosine kinases (PTKs) are key drivers of cancer.
• Genomic rearrangements create oncogenic fusion tyrosine kinases (FTKs), bypassing normal regulatory mechanisms.
• FTKs, lacking extracellular domains, resemble non-receptor tyrosine kinases (non-RTKs) in function and therapeutic targeting.

Purpose of the Study:

• To review known PTKs expressed as FTKs in various cancers.
• To outline current and emerging strategies for molecularly targeting FTKs in anti-cancer therapies.

Main Methods:

• Literature review of PTKs involved in FTK formation.
• Analysis of FTK characteristics and their implications for drug development.
• Survey of therapeutic strategies targeting FTKs.

Main Results:

• FTKs are constitutively activated through dimerization, independent of ligand binding.
• Unlike receptor tyrosine kinases (RTKs), FTKs are not amenable to antibody-based therapies.
• Targeting FTKs requires cell-permeable agents, similar to non-RTKs.

Conclusions:

• FTKs represent a significant class of oncogenic drivers in cancer.
• Effective anti-cancer strategies must consider the unique properties of FTKs for successful molecular targeting.
• Further research into novel therapeutic approaches is crucial for combating FTK-driven malignancies.